【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Tetanus Overview 9
Therapeutics Development 10
Pipeline Products for Tetanus – Overview 10
Pipeline Products for Tetanus – Comparative Analysis 11
Tetanus – Therapeutics under Development by Companies 12
Tetanus – Therapeutics under Investigation by Universities/Institutes 14
Tetanus – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Tetanus – Products under Development by Companies 19
Tetanus – Products under Investigation by Universities/Institutes 21
Tetanus – Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co., Ltd 22
Bharat Biotech International Limited 23
Biological E. Limited 24
Daiichi Sankyo Company, Limited 25
Green Cross Corporation 26
Indian Immunologicals Limited 27
LG Life Sciences, Ltd. 28
Novartis AG 29
Panacea Biotec Limited 30
Prometheon Pharma, LLC 31
Sanofi 32
Sanofi Pasteur SA 33
Serum Institute of India Limited 34
Sinovac Biotech Ltd. 35
Zydus Cadila Healthcare Limited 36
Tetanus – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
diphtheria + pertussis + tetanus vaccine – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
diphtheria + pertussis + tetanus vaccine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + tetanus+ pertussis (whole cell) vaccine – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
diphtheria + tetanus + pertussis (whole-cell) vaccine – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus vaccine – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DTaP Vaccine – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GC-1107 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GC-3111A – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tetanus + diphtheria + pertussis (acellular) vaccine – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
tetanus vaccine – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
tetanus vaccine – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tetanus vaccine – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
tetanus vaccine – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
VN-0103 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Tetanus – Recent Pipeline Updates 74
Tetanus – Dormant Projects 75
Tetanus – Discontinued Products 77
Tetanus – Product Development Milestones 78
Featured News & Press Releases 78
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 78
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 78
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 79
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 79
Feb 22, 2013: Sanofi Pasteur Announces EMA’s CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 80
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 81
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 82
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 83
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 83
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86
【レポート販売概要】
■ タイトル：破傷風(Tetanus)：治療薬開発パイプライン動向（2015年上半期版）■ 英文：Tetanus - Pipeline Review, H1 2015
■ 発行日：2015年3月11日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6264IDB
■ 調査対象地域：グローバル
- 世界の状況認識システム市場（製品、産業、応用分野、地域別分析）Situation awareness system (SAS) is the integration of different products, components and technology which can be used for perception of the elements of the environment within a volume of time and space, the comprehension of their meaning, and the projection of their status in the near future.Situation awareness is aware of the surrounding environment and detecting if any threat is existing. Deman …
- マタニティウェアの世界市場2015-2019Global Maternity Wear: Market Analysis 2015-2019 Coverings: This report covers the growth prospects of the global maternity wear market in the power industry with segmentation based on types of apparel. Market shares for key geographies include EMEA, Americas, and APAC. It also includes an insightful analysis of the leading vendors of this market such as Amoralia, Destination Maternity, Envie De F …
- AGL Energy Limited社の石油・ガス開発・生産動向及びコスト分析（2013年）AGL Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary AGL Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- パフォーマンスケミカルズ（特殊化学品）の世界市場2016-2020About the Performance Chemicals Market Performance chemicals are used for specialized applications, concentrating more on industry specific requirements compared with basic or commodity chemicals. These chemicals impart a variety of features to the products. These chemicals are used in varied applications, ranging from providing gloss and feel to day-to-day products such as textiles and leather to …
- 有機基板パッケージング材料の世界市場2015-2019About organic substrate packaging materials Organic substrates are the base layers of individual semiconductor devices and ICs on which other layers are deposited to complete a circuit. As these materials are part of the circuit, it is imperative that they are efficient conductors of electricity, and preferably thinner core materials are used to surround them in demanding system applications. A sm …
- 世界の遺伝子検査市場：製品別、エンドユーザー別、用途別、地域別Global Genetic Testing Market: About this market Technavio’s genetic testing market analysis considers sales from both equipment and consumable products. Our study also finds the sales of genetic testing in Asia, Europe, North America, and ROW. In 2019, the equipment segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing …
- 世界エンターテインメント産業におけるアニメーション及びデザインソフトウェア市場動向（2012-2016）TechNavio's analysts forecast the Global Animation and Design Software market in the Entertainment industry to grow at a CAGR of 21.10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing adoption of 3D animation software. The Global Animation and Design Software market in the Entertainment industry has also been witnessing the development …
- B型慢性肝炎の疫学的予測（～2024）EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024 Summary The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected …
- 世界のスマート・セットトップボックス及びドングル市場動向（2014-2018）About Smart STBs and Dongles STB are devices that are connected to a TV at the user's premises. These devices enable the user to receive unencrypted subscribed channels through an addressable system for viewing encrypted channels. They connect a TV to an external signal source and transform the transmitted signal into video content, which is then displayed on the screen. A smart STB is the one whi …
- 世界の湿式スクラバー市場2015The Global Wet Scrubber Industry Report 2015 is a professional and in-depth study on the current state of the Wet Scrubber industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Wet Scrubber market analysis is provided for the international markets including development trends, competitive landscape analy …
- シリコーンの世界市場予測（～2022年）：エラストマー、液体、樹脂、ゲルThe global silicone market is estimated at USD 14.20 Billion in 2017 and is projected to reach USD 18.87 Billion by 2022, at a CAGR of 5.85% between 2017 and 2022. The market is witnessing growth due to the efficient and sustainable properties of silicone which makes it suitable for use in various end-use industries and growing demand for silicone in emerging clusters of Asia Pacific and the Middl …
- 炭疽病治療の世界市場2019-2023101 pages, November 2018 About this market The increase in funding for research on anthrax vaccine across the globe is likely to boost the market growth. The new funding will allow additional vaccine characterization and inspection of mucosal immune response. Technavio’s analysts have predicted that the anthrax treatment market will register a CAGR of more than 8% by 2023. Market Overview Developm …
- 尿管癌（Ureter Cancer）：グローバル臨床試験レビュー（2014年上半期）Ureter Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Ureter Cancer Global Clinical Trials Review, H1, 2014" provides data on the Ureter Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ureter Cancer. It includes an overview of the trial numbers and their recruitment status as per the …
- フッ素系界面活性剤の世界市場：種類、用途、地域別市場分析The fluorosurfactants market size in terms of value is projected to grow at a CAGR of 5.1% between 2014 and 2019 to reach $364.1 million by 2019. North America held the largest share in fluorosurfactants market in 2013. Asia-Pacific is projected to register highest growth driven by the increasing consumptions of paint and coatings in architectural and automotive industries. Demand for paint and co …
- 水中ロボットの世界市場2015-2019About Underwater Robotics Underwater robots are used for continuous oceanic surveillance. They are designed to work in challenging environments where the safety and accessibility of divers is compromised. Underwater robots have several applications in the fields of maritime security, underwater archaeology, and marine biology. They also play an important role in the development of the Offshore ind …
